Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Year of publication
- 2012 (5) (remove)
Document Type
- Journal article (5)
Language
- English (5) (remove)
Keywords
- cancer (4)
- breast-tumors (3)
- angiogenesis (2)
- microenvironment (2)
- nude-mice (2)
- therapy (2)
- Biochemie (1)
- Biologie (1)
- adenovirus (1)
- animal-model (1)
- carcinoma (1)
- cell-line (1)
- chemotherapy (1)
- cytokine (1)
- dogs (1)
- endothelial growth-factor (1)
- glv-1h68 (1)
- hyper-IL-6 (1)
- in-vitro (1)
- matrix metalloproteinases (1)
- mice (1)
- microvascular density (1)
- model (1)
- neutrophils (1)
- oncolysis (1)
- pet dogs (1)
- prostate (1)
- vaccinia virus (1)
- virotherapy (1)
Background: Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic. Methods: Here, we describe a novel approach to optimize combination therapy of oncolytic virus and chemotherapy utilizing virus-encoding hyper-IL-6, GLV-1h90, to reduce chemotherapy-associated side effects. Results: We showed that the hyper-IL-6 cytokine was successfully produced by GLV-1h90 and was functional both in cell culture as well as in tumor-bearing animals, in which the cytokine-producing vaccinia virus strain was well tolerated. When combined with the chemotherapeutic mitomycin C, the anti-tumor effect of the oncolytic virotherapy was significantly enhanced. Moreover, hyper-IL-6 expression greatly reduced the time interval during which the mice suffered from chemotherapy-induced thrombocytopenia. Conclusion: Therefore, future clinical application would benefit from careful investigation of additional cytokine treatment to reduce chemotherapy-induced side effects.